WHAT IS CLAIMED IS:

1. A compound having the formula (I):



(I)

wherein:

R^1 is selected from:

 and  , unsubstituted or substituted with one or more substituents selected from: halogen, $-R^2$, $-O-R^2$, -CN, $-N(R^2)_2$,

Y is selected from:  , $-R^3-$ and $-R^3-O-R^3-$, where C' and C''are each independently directly or indirectly bound to R^1 to form a 5 to 7 member fused ring;

Z is absent or is selected from O, C_{1-6}alkyl, C_{1-6}alkenyl, C(O), S, SO, SO_2, NR^4, where R^4 is C_{0-6}alkyl or C_{0-6}alkenyl, where said alkyl or alkenyl is unsubstituted or is substituted with one or more substituents selected from: halogen, $-R^5$, $-O-R^5$, -CN, $-N(R^5)_2$;

A and B are each independently C_{0-4}alkyl, where a ring is formed comprising A and B, where an individual carbon atom in A and an individual carbon atom in B optionally bridge said ring, where each member of said ring is independently unsubstituted or substituted with one or more substituents selected from halogen, $-R^6$, $-O-R^6$, -CN, $-N(R^6)_2$;

W is absent or is selected from from O, C_{0-6}alkyl, C_{0-6}alkenyl, C(O), S, SO, SO_2, NR^7, where said alkyl or alkenyl is unsubstituted or is substituted with one or more substituents selected from halogen, $-R^8$, $-O-R^8$, -CN, $-N(R^8)_2$;


is unsubstituted or is substituted with one or more substituents selected from halogen, $-R^9$, $-O-R^9$, -CN, $-N(R^9)_2$;

R^2, R^3, R^4, R^5, R^6, R^7, R^8 and R^9 are each independently hydrogen, C_{0-6}alkyl, C_{0-6}alkenyl unsubstituted or substituted with one or more halogen;

and pharmaceutically acceptable salts thereof, and individual and diastereomers thereof.

2. A compound of Claim 1, wherein:

R^1 is  , unsubstituted or substituted with halogen or $-R^2$, where R^2 is C_{1-6}alkyl;

Y is -C_{1-6}alkyl, independently unsubstituted or substituted with one or more halogen;

Z is O;

A and B are each independently C_{0-4}alkyl;

W is absent;

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

3. A compound having the formula (Ia):



(Ia)

wherein:

R^1 is  , unsubstituted or substituted with halogen or $-R^2$, where R^2 is C_{1-6}alkyl, independently unsubstituted or substituted with one or more halogen;

Y is $-C_{1-6}$alkyl, independently unsubstituted or substituted with one or more halogen;

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

4. A compound having the formula (Ib):



(Ib)

wherein:

R^1 is  , unsubstituted or substituted with halogen or -R^2, where R^2 is C_{1-6}alkyl, unsubstituted or substituted with one or more halogen;

the cyclopentyl group is unsubstituted or substituted with 1-3 fluorine;

Y is -C_{1-6}alkyl, unsubstituted or substituted with one or more halogen;

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

5. A compound having the formula (Ic):



(Ic)

wherein:

R^1 is  , unsubstituted or substituted with halogen or -R^2, where R^2 is C_{1-6}alkyl, unsubstituted or substituted with one or more halogen;

R^4 is hydrogen or C_{0-6}alkyl unsubstituted or substituted with one or more halogen;

the cyclopentyl group is unsubstituted or substituted with 1-3 fluorine;

Y is -C_{1-6}alkyl, unsubstituted or substituted with one or more halogen;

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

6. A compound selected from:

5













and pharmaceutically acceptable salts thereof, and individual and diastereomers thereof.

7. A pharmaceutical composition comprising an inert carrier and a therapeutically effective amount of a compound according to Claim 1.

8. The pharmaceutical composition according to Claim 7, further comprising a second therapeutic agent selected from the group consisting of: (i) non-steroidal anti-inflammatory agents; (ii) COX-2 inhibitors; (iii) bradykinin B1 receptor antagonists; (iv) sodium channel blockers and antagonists; (v) nitric oxide synthase (NOS) inhibitors; (vi) glycine site antagonists; (vii) potassium channel openers; (viii) AMPA/kainate receptor antagonists; (ix) calcium channel antagonists; (x) GABA-A receptor modulators (e.g., a GABA- A receptor agonist); (xi) matrix metalloprotease (MMP) inhibitors; (xii) thrombolytic agents; (xiii) opioids such as morphine; (xiv) neutrophil inhibitory factor (NIF); (xv) L-Dopa; (xvi) carbidopa; (xvii) levodopa/carbidopa; (xviii) dopamine agonists such as bromocriptine, pergolide, pramipexole, ropinirole; (xix) anticholinergics; (xx) amantadine; (xxi) carbidopa; (xxii) catechol O-methyltransferase ("COMT") inhibitors such as entacapone and tolcapone; (xxiii) Monoamine oxidase B ("MAO-B") inhibitors; (xiv) opiate agonists or antagonists; (xv) 5HT receptor agonists or antagonists; (xvi) NMDA receptor agonists or antagonists; (xvii) NK1 antagonists; (xviii) selective serotonin reuptake inhibitors ("SSRI") and/or selective serotonin and norepinephrine reuptake inhibitors ("SSNRI"); (xxix) tricyclic antidepressant drugs, (xxx) norepinephrine modulators; (xxxi) lithium; (xxxii) valproate; and (xxxiii) neurontin (gabapentin).

9. The pharmaceutical composition according to Claim 7 useful for the treatment of pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, and ischemic brain injury including stroke.

10. The pharmaceutical composition according to Claim 7 useful for the treatment of Parkinson's disease.

11. A method for treating or preventing pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

12. A method for treating or preventing chronic, visceral, inflammatory and neuropathic pain syndromes in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

13. A method for treating or preventing pain resulting from, or associated with, traumatic nerve injury, nerve compression or entrapment, postherpetic neuralgia, trigeminal neuralgia, diabetic neuropathy, cancer and chemotherapy, in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

14. A method for treating or preventing chronic lower back pain in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

15. A method for treating or preventing phantom limb pain in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

16. A method for treating or preventing HIV- and HIV treatment-induced neuropathy, chronic pelvic pain, neuroma pain, complex regional pain syndrome, chronic arthritic pain and related neuralgias in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

17. A method for treating or preventing epilepsy and partial and generalized tonic seizures in a patient in need thereof comprising administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.